Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
12.23
-0.03 (-0.24%)
Jul 24, 2025, 4:00 PM - Market closed

Company Description

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom.

Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases.

The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.

Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Atara Biotherapeutics, Inc.
Atara Biotherapeutics logo
CountryUnited States
Founded2012
IPO DateOct 16, 2014
IndustryBiotechnology
SectorHealthcare
Employees153
CEOAnhco Nguyen

Contact Details

Address:
1280 Rancho Conejo Blvd
Thousand Oaks, California 91320
United States
Phone805 623 4211
Websiteatarabio.com

Stock Details

Ticker SymbolATRA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001604464
CUSIP Number046513107
ISIN NumberUS0465132068
Employer ID46-0920988
SIC Code2836

Key Executives

NamePosition
Dr. Anhco Nguyen Ph.D.President, Chief Executive Officer and Director
Yanina Grant-HuertaChief Accounting Officer and Principal Accounting Officer
Alex ChapmanVice President of Corporate Communications and Investor Relations
John ChaoHead of Legal
Jim SesicSenior Vice President of Regulatory Affairs

Latest SEC Filings

DateTypeTitle
Jul 14, 20258-KCurrent Report
Jun 11, 20258-KCurrent Report
May 23, 2025SCHEDULE 13DFiling
May 21, 2025SCHEDULE 13DFiling
May 16, 2025144Filing
May 16, 2025144Filing
May 16, 2025SCHEDULE 13D/AFiling
May 16, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025424B5Filing